Comparative in Biological Technology

International Milk Genomics & Human Health Symposium Speaker Program Announced

... feature presentations on:   Using comparative genomics to understand milk's unique biological ... The annotation of the lactation genome; comparative transcriptomics and genomics of mammalian ... of mammary development; Insights from comparative genomics/the Lactoscan project; Milk and ...

Amarin Announces Financial Results for Fourth Quarter and Full Year 2007

... million for the fourth quarter of 2007 from the comparative period in 2006 is primarily due to the ... was due to options granted since the end of the comparative period. Twelve months ended December 31, 2007 ... with an operating loss of $28.1 million for the comparative period in 2006. The 2007 increase in ...

IDEXX Laboratories Announces First Quarter Results

... - - - Non-GAAP comparative measurements(3) $ 129,836 $ 109,827 ... - (0.02) - Non-GAAP comparative measurements(3) $ 26,079 $ 21,931 ... financial measures to evaluate the Company's comparative financial performance. The specified items that ...

Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing

... an emergency. Researchers have now developed a comparative genomics strategy to drastically reduce the time ... to quickly characterize an outbreak strain by comparative analysis. In the context of an outbreak, a quick ... high-throughput sequencing technology and the comparative genomic analysis strategy outlined in this work ...

Acrongenomics on Track to Acquire Molecular Vision

... used in Pathology Laboratories. The results of comparative trial measuring creatinine in urine will be ... results have shown good correlation. A further comparative trial measuring vitamin C is underway and various blood based tests are being planned. Once these comparative trials are completed, the company will then ...

HealthCore Responds to Need for Real-world Health Outcomes Information on Drugs and Devices with Physician Network and Prospective Effectiveness Research

... and shorten the life-cycle of prospective effectiveness research and comparative effectiveness research initiatives, such as those funded by the $1.1 ... studies, respond to health surveys, and recruit and enroll patients in comparative effectiveness studies. "Our immediate access to physicians will help ...

Renowned Stem Cell Researcher Files Study Results With Stemedica

... bone injuries using autologous stem cells, allogeneic stem cells and comparative traditional treatment therapies, indicated that the use of adult stem ... bone injuries using autologous stem cells, allogeneic stem cells and comparative traditional treatment therapies. "The results that Dr. ...

Helix BioPharma Announces Q2 2009 Financial Results

... for a loss per common share of $0.08 and $0.13, respectively. In the comparative three and six month periods ended January 31, 2008, the Company recorded a ... raising and investor relations services. Capital raising services in the comparative three and six month periods ended January 31, 2008 relate to the December ...

QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy

... central nervous system (CNS) disorders, announced today initiation of a comparative study to evaluate the efficacy and safety profile of MoxDuoIR(TM) against ... experiencing post-surgery (bunionectomy) pain. Data collected from the comparative study will be used to select the optimal dose regimen and sample sizes for ...

Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months

... per share from the previous quarter ($0.28). Results of Operations The comparative results of operations are as follows: (In thousands except per share ... items during the 2008 and 2007 third quarter and first nine months. The comparative results of operations - as adjusted are as follows: (In thousands except ...

Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008

... for a loss per common share of $0.03 and $0.11, respectively. In the comparative three and nine month periods ended April 30, 2007, the Company recorded ... for both L-DOS47 and Topical Interferon Alpha-2b were less than in the comparative three and nine month periods ended April 30, 2007. Higher research and ...

First electrophysical recording of sleep in a wild animal

... If animals behave differently in captivity (where all previous comparative studies were performed) than they do in the wild, measuring their brain ... intricate tropical forest environment. It also will lead to more refined, comparative sleep research. The beauty of the automated telemetry system is that it ...

Angiotech announces results for the fourth quarter ended December 31, 2007

... deferred financing costs. k. Tax effects of adjustments for the period. comparative for 2006 also includes non-recurring retroactive tax adjustment of ... the period, including the reversal of tax reserves previously booked. comparative for 2006 also includes non-recurring retroactive tax adjustment of ...

European Commission gives grant to investigate transatlantic oversight of nanotech

... of the project is threefold: To produce high quality analysis of the comparative dimensions of nanotechnologies regulation in the EU and U.S.; To ... The project will involve a research report and analytical papers based on comparative research, a major international conference to be held at Chatham House and ...

Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year

... as address short-term fiscal challenges. Results of Operations The comparative results of operations are as follows: (In thousands except per share ... items during the 2007 and 2006 fourth quarter and full year. The comparative results of operations -- as adjusted are as follows: (In thousands except ...

Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD)

... "Comprehensive Aneuploidy Screening in Single Cells Using Microarray comparative Genomic Hybridization Methods: Implications for Preimplantation Genetic ... abnormalities. Specifically the company has evolved array-based comparative Genomic Hybridization (aCGH) by developing microarrays that utilize ...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

... further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial ...

ERT Reports Second Quarter 2009 Results

... device and related industries, announced today results for the second quarter and six-month period ended June 30, 2009. Unless otherwise noted, all comparative numbers refer to changes from the same period a year ago. Highlights of the second quarter of 2009 were: Revenue was $24.2 ...

Caliper Life Sciences Reports Second Quarter 2009 Results

... were $32.1 million compared to $34.0 million for the second quarter of 2008. Divestitures and foreign currency translation negatively impacted comparative revenues by $3.3 million, or 10%, and $1.0 million, or 3%, respectively. The Company narrowed its net loss to $4.1 million ($0.08 per share) in the ...

Sanofi-aventis Announces Second Quarter 2009 Results

... success of Plavix((R)), Myslee((R)) and Allegra((R)), despite the sales growth comparison being subdued by the fact that the 2008 second-quarter comparative included sales of the active ingredient of Aprovel((R)) to our local partners. Latin America, where net sales rose by 5.7%, was boosted by the ...

SEQUENOM Announces Launch of MassARRAY Compact 96 System

... including SNP genotyping and allelotyping, CNV analysis, quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. About SEQUENOM SEQUENOM is a life sciences ...

Digitas Health Expands Adding Two Key Locations

... 2007 (2) HM Revenue & Customs , 2007 (3) Milken Institute, The Greater Philadelphia Life Sciences Cluster 2009: An Economic and comparative Assessment , May 2009 (4) Deloitte research and Massachusetts Biotechnology Council, Strategic Outlook for 2015 and Strategic Plan , May 2009 ...

QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy

... and BEDMINSTER, N.J., July 23 /PRNewswire-FirstCall/ -- QRxPharma Limited (Pink Sheets: QRXPY; ASX: QRX) announced today the initiation of a Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of MoxDuo(TM) IV (intravenous morphine and oxycodone) versus IV morphine alone for the ...

Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference

... investors," says Stephen M. Dunn, Managing Director of Life Sciences Research at LifeTech Capital Group. "With the government's recent demands for comparative effectiveness of drugs, there is a corresponding increase in demand for companies with novel, breakthrough approaches. We're pleased to have such a ...

Spherix Announces Termination of Arla License Agreement

... Diabetes Type 2 diabetes mellitus (T2DM) is a disease that is characterized by elevated blood glucose in the context of insulin resistance and comparative insulin deficiency. While T2DM is often initially managed by increasing exercise in conjunction with dietary modification, medications are usually ...

Spherix Announces Full-Scale Production of Pharmaceutical Tagatose

... Diabetes Type 2 diabetes mellitus (T2DM) is a disease that is characterized by elevated blood glucose in the context of insulin resistance and comparative insulin deficiency. While T2DM is often initially managed by increasing exercise in conjunction with dietary modification, medications are usually ...

Pharmaceutical Institute Launches New E-Course Focused on Health Policy

... or proposed "movement" on five other pressing issues related to healthcare quality and cost, including Medicare Part D non-interference clause, comparative effectiveness research, drug reimportation, health information technology, and follow-on biologics. The discussion spotlights concerns that these ...

Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update

... respectively, for the three and nine month periods ended April 30, 2009, for a loss per common share of $0.08 and $0.21, respectively. In the comparative three and nine month periods ended April 30, 2008, the Company recorded a loss of $1,139,000 and $4,309,000, respectively, for a loss per common ...

Kornberg Associates Architects Selected to Design Research Areas of Malaysia Genome Institute

... populous state; located in the center of the country), engages in discovery research of tropical bioresources through projects on genome sequencing, comparative and functional genomics, and structural biology. "We selected Kornberg Associates | Architects to ensure that the new project will meet ...

New and Expanded Free Tutorials on UCSC Genome Browser Now Available

... of California, Santa Cruz. Director and HHMI investigator David Haussler leads a team of scientists, engineers and students in the study and comparative analysis of mammalian and model organism genomes. Research Scientist Jim Kent heads up the engineering team that develops and maintains the UCSC ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... of the head and neck, reporting a 74% ORR in the cetuximab plus radiotherapy arm. "Notwithstanding limitations in inter-study comparisons, the comparative data are reassuring," noted Dr. Leonardo Viana Nicacio, M.D., Director, Clinical Affairs for YM BioSciences. Pfister DG et al (J Clin Oncol. 2006 ...

Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients

... attributed to overimmunosuppression. This study was published in the March 2007 issue of the American Journal of Transplantation. A second comparative clinical study was the ELITE-Symphony study, supported by Hoffmann La Roche, Inc. This study was a prospective, randomized, open-label, ...

Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting

... is Comparable to Risperidone in Analyses of a Placebo- and Risperidone-Controlled Clinical Trial for Schizophrenia. NR1-026 The comparative Efficacy of Iloperidone and Haloperidol Across Four Short-Term Controlled Trials. The following four posters discussing genetic and ...

ZyGEM Releases Application Note Showing its DNA Extraction Kits Rapidly Produce High Yields of Quality DNA

... CEO of ZyGEM. "Since small animal genotyping is a critical but often time-consuming aspect of biomedical research, we are pleased to make this comparative data available to our growing customer base." The results included in this application note show that in a PCR assay gel analysis, the prep ...

Ambry Genetics Announces the Addition of Array CGH Services Through Partnership With Baylor College of Medicine

... ALISO VIEJO, Calif., May 5 /PRNewswire/ -- Ambry Genetics Corp. announces the implementation of comparative Genomic Hybridization (CGH) using oligonucleotide arrays through a partnership with Baylor College of Medicine . Large chromosomal abnormalities ...

ERT Reports First Quarter 2009 Results

... to the biopharmaceutical, medical device, and related industries, announced today results for the first quarter of 2009. Unless otherwise noted, all comparative numbers refer to changes from the same period a year ago. Highlights of the first quarter were: Quarterly net revenue was $23.8 ...

ViroPharma Incorporated Reports First Quarter 2009 Financial Results

... January 2009, offset by lower sales volumes. Cost of sales increased over the prior year by $2.0 million due to the launch of Cinryze. In the comparative period in 2008, the Company only had cost of sales related to Vancocin. As part of our October 2008 purchase of Lev, we acquired Cinryze inventory ...

Real Time Genomics to Show SLIM Search(TM) Technology on Windows HPC Server 2008 at Bio-IT World Conference

... Time Genomics will demonstrate solutions for deep genomic analysis at Bio-IT World Conference 2009 in Boston, April 27-29. Two applications, one for comparative genomics and another for gene expression, show genome-scale computation in real time using a compute cluster on Windows HPC Server 2008. The ...

DNA duplication: A mechanism for 'survival of the fittest'

... DNA duplications occurred between 40 and 80 million years ago. So, the bioinformaticians worked to refine the dating. Thanks to their expertise in comparative genome studies and their extensive database, they were able to make a very precise dating of the duplications on the basis of standard evolution ...

Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference

... JAK2 drug candidate for the treatment of myeloprofilerative disorders (MPDs). Data for CYT387 in a panel of in vitro assays will be shown, as will comparative data with other described JAK inhibitors. A separate poster on Cytopia's vascular disrupting agent (VDA), CYT997, has also been presented at the ...